Navigation Links
Vitamin K does not stem BMD decline in postmenopausal women with osteopenia
Date:10/13/2008

In a randomized controlled trial called the "Evaluate the Clinical use of vitamin K Supplementation in Postmenopausal Women with Osteopenia" (ECKO) trial, Angela Cheung and colleagues at the University of Toronto found that a high dose daily vitamin K1 supplement did not protect against age-related bone mineral density (BMD) decline. However, as reported in this week's PLoS Medicine, the findings also suggest that vitamin K1 may protect against fracture and cancer in postmenopausal women with osteopenia.

Dr. Cheung and colleagues randomized 440 postmenopausal women with osteopenia to receive either 5 mg of vitamin K1 or a placebo daily for two years. Two hundred and sixty one of these women continued their treatment for two more years to gather information about the long-term effects of vitamin K1 supplementation.

After two years and after four years, lower back and hip measurements of bone mineral density (BMD) had decreased by similar amounts in both the vitamin K and the placebo groups.

Over the four-year period, fewer women in the vitamin K group had fractures (9 versus 20 women in the placebo group) and fewer women had cancer (3 versus 12). Vitamin K supplementation was well tolerated over the four-year period and adverse health effects were similar in the two treatment groups, report the researchers. They emphasize that the study was not powered to examine fractures or cancers and the numbers were small, therefore the findings must be interpreted with caution.

The researchers say that larger studies are needed to examine the effect of vitamin K1 on fractures and on cancer and, until these are done, high dose vitamin K1 supplementation should not be recommended for the prevention of osteoporosis.

In the US, 10 million people have osteoporosis and 18 million have osteopenia, a milder condition that precedes osteoporosis.


'/>"/>

Contact: Andrew Hyde
press@plos.org
44-122-346-3330
Public Library of Science
Source:Eurekalert

Page: 1

Related biology news :

1. Lack of vitamin D linked to Parkinsons disease
2. Vitamin D a key player in overall health of several body organs, says UC Riverside biochemist
3. Vitamin C supplements may reduce benefit from wide range of anti-cancer drugs
4. Dont forget the vitamin A when working with its carrier protein
5. Variant of vitamin D receptor gene linked to melanoma risk
6. Majority of osteoporosis patients not receiving calcium and vitamin D with treatment
7. Vitamin A pushes breast cancer to form blood vessel cells
8. Researchers identify cancer preventive properties in common vitamin supplement
9. Newborn vitamin A reduces infant mortality
10. New technology may prevent vitamin B12 deficient seniors and vegetarians from needing injections
11. Vitamin D: New way to treat heart failure?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/14/2015)...  HYPR Corp. today announced it has joined ... tm , an industry consortium transforming online authentication ... technology and collaborate to deliver open specifications for ... and private, and easier to use. ... sensitive user information and eliminates the dependency on ...
(Date:4/10/2015)... 10, 2015 Research and Markets ... "Security Competitive Profiles - NEC" report to ... NEC will continue to supply a range of ... with a company focus on the development of a ... Winning opportunities in the Asia-Pacific ...
(Date:4/2/2015)... , April 2, 2015 ... DERMALOG by far outperforms the strongest competitors, showing ... high accuracy, the system is capable of a ... speed proves up to be ten times faster ... its runner-up performance.      (Photo: ...
Breaking Biology News(10 mins):HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3NEC Security Competitive Profile 2015 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3
... drugs currently studied in clinical trials appears to reduce ... at Georgetown University Medical Center report in an upcoming ... They say the results suggest that this class of ... been able to do-- prevent the long-term and continuing ...
... the specific biological mechanisms believed to lead to ... Diamond Blackfan anemia (DBA). Scientists say with further ... to current thinking about treatment for this disease ... George Thomas, PhD, Stefano Fumagalli, PhD, ...
... or ,gloopiness, of different parts of cancer cells increases ... according to new images that provide fundamental insights into ... today (15 March). The ... cells whilst they are dying as a result of ...
Cached Biology News:Alzheimer's disease therapeutic prevents long-term damage from TBI in pre-clinical studies 2Alzheimer's disease therapeutic prevents long-term damage from TBI in pre-clinical studies 3Cellular discovery may lead to targeted treatment for rare form of anemia 2Cellular discovery may lead to targeted treatment for rare form of anemia 3A sticky business -- how cancer cells become more 'gloopy' as they die 2
(Date:5/22/2015)... Charm Sciences, Inc. is pleased ... (USDA), Grain Inspection, Packers and Stockyards Administration (GIPSA) ... Sciences to monitor aflatoxin in grains utilizing Charm’s ... FAST Aflatoxin Quantitative Test (solvent-based). , The Charm ... Water Extraction Technology to extract aflatoxin from the ...
(Date:5/21/2015)... May 21, 2015 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" ... company that develops and commercializes proprietary technologies and products ... operational results for the second fiscal quarter ended March ... Company continued to advance business with our existing customers ... , President and CEO of SQI. "The delivery of ...
(Date:5/21/2015)... , May 21, 2015  Susan Hedstrom, Executive ... a nonprofit organization dedicated to supporting research to ... (PWS), announced today that FPWR has received the ... Irina Shaulov contributed $1 million in support ... "Our gift ...
(Date:5/21/2015)...  The EveryLife Foundation for Rare Diseases applauded ... Amy Klobuchar (D-MN) today for introducing the ... or OPEN ACT. Supported by more ... bipartisan legislation promises to rapidly bring hundreds of ... patients by incentivizing drug makers to "repurpose" approved ...
Breaking Biology Technology:USDA-GIPSA (FGIS) Awards 5 Year Contract for Aflatoxin Tests to Charm Sciences 2SQI Diagnostics Reports Second Quarter Financial Results 2SQI Diagnostics Reports Second Quarter Financial Results 3SQI Diagnostics Reports Second Quarter Financial Results 4SQI Diagnostics Reports Second Quarter Financial Results 5SQI Diagnostics Reports Second Quarter Financial Results 6SQI Diagnostics Reports Second Quarter Financial Results 7SQI Diagnostics Reports Second Quarter Financial Results 8The Foundation for Prader-Willi Research Receives $1M Contribution in Support of Clinical Initiatives 2Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2
... , , ATLANTA, Sept. ... Board: EAUI), a leading provider of electrolyzed water for high-volume, ... trial with a leading international beverage bottling company enabling the ... sanitation process for CIP (Clean-in-Place) applications. EAU,s electrolyzed water ...
... , ... Expressionist modules Refiner Array and Analyst deliver expanded processing and reporting functionalities. ... Basel, ... leading provider of in silico solutions for pharmaceutical R&D and related life sciences, ...
... , , , CLEVELAND, ... GanedenBC30(R) , today announced the launch of the first ... the latest in a number of innovative probiotic-enhanced products introduced by Ganeden ... recent popularity of thin strips as a supplement delivery system led Ganeden ...
Cached Biology Technology:EAU Completes Approval Process for Electrolyzed Water as Sanitation Process for Industrial Clean-in-Place Application 2EAU Completes Approval Process for Electrolyzed Water as Sanitation Process for Industrial Clean-in-Place Application 3EAU Completes Approval Process for Electrolyzed Water as Sanitation Process for Industrial Clean-in-Place Application 4Genedata Expressionist with New Transcriptomics Biomarker Capabilities Advances Drug Development for Personalized Medicine 2Genedata Expressionist with New Transcriptomics Biomarker Capabilities Advances Drug Development for Personalized Medicine 3Genedata Expressionist with New Transcriptomics Biomarker Capabilities Advances Drug Development for Personalized Medicine 4Ganeden Biotech Introduces the First Probiotic Thin Strip 2Ganeden Biotech Introduces the First Probiotic Thin Strip 3
Anti-human CD48/BLAST-1, clone MEM102, Monoclonal Antibody...
Raf-1 (C-12)-G...
... DuoSet ELISA Development kit contains the basic ... ELISAs to measure natural and recombinant mouse ... and serum. Each kit contains sufficient materials ... plates, provided that the following conditions are ...
E1A (adenovirus early region 1)...
Biology Products: